EBD Group is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Partner at Canaan Partners
Julie Papanek is as Partner at Canaan Partners’ where she leads investments across biopharmaceuticals, life science tools, and digital health. Canaan Partners is an early stage technology and healthcare venture capital firm with over $3.5 billion under management. Julie brings operation expertise spanning development and commercial positions at Genentech. At Canaan Partners, she led investments in Cellular Research (acquired by Becton Dickinson) and Protagonist Therapeutics (IPO in 2016). During her 3 years at Canaan Partners, Julie also co-sponsored Canaan’s investments in Chrono Therapeutics, Glooko, Unchained Labs, and Truveris. She also observed on the boards of CytomX, Aldea Pharmaceuticaals and Dermira. Julie holds an MBA from Stanford's Graduate School of Business, an MPhil from Cambridge University in BioScience Enterprise and a B.S. from Yale University in Molecular Biophysics and Biochemistry.